115 related articles for article (PubMed ID: 8655464)
1. Hypocellular acute myeloid leukemia: the Rochester (New York) experience.
Tuzuner N; Cox C; Rowe JM; Bennett JM
Hematol Pathol; 1995; 9(3-4):195-203. PubMed ID: 8655464
[TBL] [Abstract][Full Text] [Related]
2. Acute erythroid neoplastic proliferations. A biological study based on 62 patients.
Domingo-Claros A; Larriba I; Rozman M; Irriguible D; Vallespí T; Aventin A; Ayats R; Millá F; Solé F; Florensa L; Gallart M; Tuset E; Lopez C; Woessner S
Haematologica; 2002 Feb; 87(2):148-53. PubMed ID: 11836165
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
Dick FR; Burns CP; Weiner GJ; Heckman KD
Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
5. [Hypocellular acute leukemia].
Tomonaga M
Rinsho Ketsueki; 1995 May; 36(5):457-64. PubMed ID: 7783351
[TBL] [Abstract][Full Text] [Related]
6. Haematologic and immunophenotypic profile of acute myeloid leukemia: an experience of Tata Memorial Hospital.
Ghosh S; Shinde SC; Kumaran GS; Sapre RS; Dhond SR; Badrinath Y; Ansari R; Kumar A; Mahadik S; Chougule AB; Nair CN
Indian J Cancer; 2003; 40(2):71-6. PubMed ID: 14716122
[TBL] [Abstract][Full Text] [Related]
7. [Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin].
Lemez P; Gáliková J; Haas T
Vnitr Lek; 1999 Jun; 45(6):342-6. PubMed ID: 11045169
[TBL] [Abstract][Full Text] [Related]
8. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category.
Ghannadan M; Wimazal F; Simonitsch I; Sperr WR; Mayerhofer M; Sillaber C; Hauswirth AW; Gadner H; Chott A; Horny HP; Lechner K; Valent P
Am J Clin Pathol; 2003 May; 119(5):663-71. PubMed ID: 12760284
[TBL] [Abstract][Full Text] [Related]
10. Do de novo acute myeloid leukemias with normal cytogenetics involve two main prognostic categories distinguished by the presence of erythroblastic and/or megakaryocytic dysplasia?
Lemez P; Gáliková J; Haas T
Neoplasma; 2000; 47(1):41-7. PubMed ID: 10870686
[TBL] [Abstract][Full Text] [Related]
11. Clinical and morphological features of cases of trisomy 13 in acute non-lymphocytic leukemia.
Soni M; Brody J; Allen SL; Schulman P; Kolitz J; Rai K; Broome JD; Koduru PR
Leukemia; 1996 Apr; 10(4):619-23. PubMed ID: 8618437
[TBL] [Abstract][Full Text] [Related]
12. [Clinical analysis of HLA-DR-negative non-M3 AML].
Mori H; Sakai H; Sanada M; Shimamoto K; Sasaki S; Azuma R; Higuchi T; Harada H; Niikura H; Omine M; Fujita K; Takahashi N
Rinsho Ketsueki; 2007 Jul; 48(7):547-53. PubMed ID: 17695303
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
14. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
[TBL] [Abstract][Full Text] [Related]
16. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
17. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
[TBL] [Abstract][Full Text] [Related]
18. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
19. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
20. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
